Body dysmorphic disorder: from clinical aspects to treatment

Detalhes bibliográficos
Autor(a) principal: Carla Alexandra da Silva Carneiro
Data de Publicação: 2021
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/134421
Resumo: Body dysmorphic disorder (BDD), also known as dysmorphophobia, is a relatively common disorder, with a point prevalence of 0.7% to 2.4% among the general population, that consists of a distressing or impairing preoccupation with imagined or slight defects in appearance, associated with repetitive behaviors and where insight regarding the appearance beliefs is often poor. Failure to recognize and diagnose this disorder can lead to poor physical and psychiatric outcomes for patients, thus it is important for the physicians to be aware to the clinical aspects of this disorder, for early detection of the condition and consequently give an appropriate treatment to the patients. The criteria for diagnosing BDD are described according to the DSM-IV and DSM 5. The search for bibliographic information was held on the Pubmed platform with the keywords: body dysmorphic disorder. Only articles that obeyed the following conditions were analyzed: written in English or Portuguese and with free full access; having analyzed 494 articles, between 1994 and 2020. There were included 41 articles that appeared to be relevant for the Body dysmorphic disorder, and which aimed to clarify the clinical, diagnostic and therapeutic aspects of this clinical entity. Serotonin reuptake inhibitors (SRIs) are currently considered the medication treatment of choice. According to all studies conducted do date, for an improvement of symptoms, a relatively high SRI dose and at least 12 weeks of treatment is often needed. The psychosocial treatment of choice is cognitive behavioral therapy. Additional treatment development and efficacy studies are urgently needed to better understand the therapeutic approach of this entity, in order to improve the quality of life of these patients.
id RCAP_3e81cbe9577e996ce15feded0d1e7bfe
oai_identifier_str oai:repositorio-aberto.up.pt:10216/134421
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Body dysmorphic disorder: from clinical aspects to treatmentMedicina clínicaClinical medicineBody dysmorphic disorder (BDD), also known as dysmorphophobia, is a relatively common disorder, with a point prevalence of 0.7% to 2.4% among the general population, that consists of a distressing or impairing preoccupation with imagined or slight defects in appearance, associated with repetitive behaviors and where insight regarding the appearance beliefs is often poor. Failure to recognize and diagnose this disorder can lead to poor physical and psychiatric outcomes for patients, thus it is important for the physicians to be aware to the clinical aspects of this disorder, for early detection of the condition and consequently give an appropriate treatment to the patients. The criteria for diagnosing BDD are described according to the DSM-IV and DSM 5. The search for bibliographic information was held on the Pubmed platform with the keywords: body dysmorphic disorder. Only articles that obeyed the following conditions were analyzed: written in English or Portuguese and with free full access; having analyzed 494 articles, between 1994 and 2020. There were included 41 articles that appeared to be relevant for the Body dysmorphic disorder, and which aimed to clarify the clinical, diagnostic and therapeutic aspects of this clinical entity. Serotonin reuptake inhibitors (SRIs) are currently considered the medication treatment of choice. According to all studies conducted do date, for an improvement of symptoms, a relatively high SRI dose and at least 12 weeks of treatment is often needed. The psychosocial treatment of choice is cognitive behavioral therapy. Additional treatment development and efficacy studies are urgently needed to better understand the therapeutic approach of this entity, in order to improve the quality of life of these patients.2021-04-262021-04-26T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/134421TID:202848213engCarla Alexandra da Silva Carneiroinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T15:13:33Zoai:repositorio-aberto.up.pt:10216/134421Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:18:27.261342Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Body dysmorphic disorder: from clinical aspects to treatment
title Body dysmorphic disorder: from clinical aspects to treatment
spellingShingle Body dysmorphic disorder: from clinical aspects to treatment
Carla Alexandra da Silva Carneiro
Medicina clínica
Clinical medicine
title_short Body dysmorphic disorder: from clinical aspects to treatment
title_full Body dysmorphic disorder: from clinical aspects to treatment
title_fullStr Body dysmorphic disorder: from clinical aspects to treatment
title_full_unstemmed Body dysmorphic disorder: from clinical aspects to treatment
title_sort Body dysmorphic disorder: from clinical aspects to treatment
author Carla Alexandra da Silva Carneiro
author_facet Carla Alexandra da Silva Carneiro
author_role author
dc.contributor.author.fl_str_mv Carla Alexandra da Silva Carneiro
dc.subject.por.fl_str_mv Medicina clínica
Clinical medicine
topic Medicina clínica
Clinical medicine
description Body dysmorphic disorder (BDD), also known as dysmorphophobia, is a relatively common disorder, with a point prevalence of 0.7% to 2.4% among the general population, that consists of a distressing or impairing preoccupation with imagined or slight defects in appearance, associated with repetitive behaviors and where insight regarding the appearance beliefs is often poor. Failure to recognize and diagnose this disorder can lead to poor physical and psychiatric outcomes for patients, thus it is important for the physicians to be aware to the clinical aspects of this disorder, for early detection of the condition and consequently give an appropriate treatment to the patients. The criteria for diagnosing BDD are described according to the DSM-IV and DSM 5. The search for bibliographic information was held on the Pubmed platform with the keywords: body dysmorphic disorder. Only articles that obeyed the following conditions were analyzed: written in English or Portuguese and with free full access; having analyzed 494 articles, between 1994 and 2020. There were included 41 articles that appeared to be relevant for the Body dysmorphic disorder, and which aimed to clarify the clinical, diagnostic and therapeutic aspects of this clinical entity. Serotonin reuptake inhibitors (SRIs) are currently considered the medication treatment of choice. According to all studies conducted do date, for an improvement of symptoms, a relatively high SRI dose and at least 12 weeks of treatment is often needed. The psychosocial treatment of choice is cognitive behavioral therapy. Additional treatment development and efficacy studies are urgently needed to better understand the therapeutic approach of this entity, in order to improve the quality of life of these patients.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-26
2021-04-26T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/134421
TID:202848213
url https://hdl.handle.net/10216/134421
identifier_str_mv TID:202848213
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136103609925632